Automation of fluorescent in situ hybridization (FISH) leading to cost savings and consistent high-quality results.

Q: What type of study is this?

This is a Quantitative Study study (also classified as: Experimental Study).

Grace Kwon; Aaron Blackley; Kathryn Perkinson; Rex C. Bentley; Elizabeth N. Pavlisko; Diana M. Cardona

doi:10.1136/jcp-2025-210119

September 17, 2025

Automation of fluorescent in situ hybridization (FISH) leading to cost savings and consistent high-quality results.

View at Publisher

Ask AI

Bookmark

Share

Key Points

Automation of HER2 FISH testing led to a concordance rate of 98% compared to the manual method.
The Leica BOND-III platform achieved a sensitivity of 0.95 and specificity of 0.97 for breast cancer HER2 tests.
Significant decreases in technical hands-on time and supply costs were noted with the new automated platform.
Implementation of the Leica BOND-III into an existing lab setup resulted in streamlined HER2 testing processes.

Implication

This validation of the Leica BOND-III platform reveals significant reductions in hands-on time and consistent outcomes for HER2 testing in breast and gastric cancers.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kwon et al. (2025) studied this question.

synapsesocial.com/papers/68d466be31b076d99fa6592b https://doi.org/10.1136/jcp-2025-210119

View at Publisher

Ask AI

Bookmark

Share

Automation of fluorescent in situ hybridization (FISH) leading to cost savings and consistent high-quality results.

Key Points

Implication

Abstract

Discussion

Cite This Study

Automation of fluorescent in situ hybridization (FISH) leading to cost savings and consistent high-quality results.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers